Compare COO & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COO | SF |
|---|---|---|
| Founded | 1980 | 1890 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 11.4B |
| IPO Year | N/A | N/A |
| Metric | COO | SF |
|---|---|---|
| Price | $81.36 | $126.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $85.82 | ★ $126.88 |
| AVG Volume (30 Days) | ★ 3.3M | 708.5K |
| Earning Date | 12-04-2025 | 10-22-2025 |
| Dividend Yield | N/A | ★ 1.46% |
| EPS Growth | N/A | ★ 2.14 |
| EPS | 1.87 | ★ 5.66 |
| Revenue | $4,092,400,000.00 | ★ $5,293,276,000.00 |
| Revenue This Year | $6.66 | $13.43 |
| Revenue Next Year | $5.54 | $11.00 |
| P/E Ratio | $43.53 | ★ $22.32 |
| Revenue Growth | 5.06 | ★ 11.76 |
| 52 Week Low | $61.78 | $73.27 |
| 52 Week High | $104.47 | $126.69 |
| Indicator | COO | SF |
|---|---|---|
| Relative Strength Index (RSI) | 72.89 | 65.85 |
| Support Level | $75.25 | $118.82 |
| Resistance Level | $78.69 | $122.52 |
| Average True Range (ATR) | 2.48 | 3.20 |
| MACD | 0.47 | 0.47 |
| Stochastic Oscillator | 55.39 | 96.77 |
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Stifel Financial Corp is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its world-wide wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.